Collagen Diseases  >>  MK-8457  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-8457 / Merck (MSD)
NCT01569152 / 2012-000439-17: Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)

Terminated
2
82
NA
MK-8457 100 mg, Dose-Matched Placebo, Methotrexate, MTX
Merck Sharp & Dohme LLC
Rheumatoid Arthritis (RA)
10/13
10/13

Download Options